Business
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\nHLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nTORONTO, Oct. 14, 2025 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its partner, Amarin Corporation plc (NASDAQ: AMRN) announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress (\"CCC\") in Quebec City, from October 23 to 26, 2025. These presentations reflect the continued commitment of HLS and Amarin to advancing the broader therapeutic potential of Icosapent Ethyl (\"IPE\") and Eicosapentaenoic Acid (\"EPA\"), further highlighting their dedication to improving cardiovascular care for appropriate at-risk patients.\nData to be presented at CCC 2025 highlights the clinical value of IPE for cardiometabolic conditions as well as the further attempts to explore the mechanistic effects of EPA on atherogenic lipoproteins and in endothelial cells during inflammation when combined with a GLP-1 receptor agonist.\nFeatured abstracts to be presented by international academic collaborators at CCC 2025 include:\nPoster Presentation\nENCORE: Icosapent Ethyl Reduces CVD Risk in Cardiovascular-Kidney-Metabolic Syndrome: REDUCE-IT CKMMichael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A. Jacobson, Ph. Gabriel Steg, Steven B. Ketchum, Jean-Claude Tardif, Christie M. Ballantyne- Available October 24, 5:30pm ET- Board 68High Glucose Enhanced Lipoprotein(a) [Lp(a)] Oxidation in a Manner Inhibited by Eicosapentaenoic Acid (EPA) In VitroSamuel C.R. Sherratt, Ph.D., Peter Libby, M.D., Deepak L. Bhatt, M.D., M.P.H., R. Preston Mason, Ph.D.- Supported by HLS- Available October 24, 5:30pm ET- Board 75Eicosapentaenoic Acid (EPA) and a GLP-1 Receptor Agonist Caused Synergistic Changes in Protein Expression and Mediators of Endothelial Endoplasmic Reticulum Function During Inflamma...